Enterprise Value
58.55M
Cash
33.71M
Avg Qtr Burn
-10.12M
Short % of Float
20.18%
Insider Ownership
60.70%
Institutional Own.
10.64%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration | BLA Submission | |
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration | BLA FDA meeting | |
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Diabetes, Eye disease , Human herpesvirus 6, Epstein-Barr virus, Adenovirus, BK virus, Cytomegalovirus, Diabetic macular edema | Phase 3 Initiation | |
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease | Phase 3 Initiation |